

REMARKS

This amendment is submitted to cancel claims in order to reduce the filing fee. There is no new matter added, and entry of the amendment is respectfully requested.

This application contains a Sequence Listing. The computer-readable form in this application is identical with that filed in application no. 09/779,323 filed September 8, 2001. In accordance with 37 CFR 1.821(e), please use the last, computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. The content of the attached Sequence Listing and of the computer readable form filed in the parent application is the same. No new matter is added.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: November 14, 2003



Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097